Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CyclopharmASX:CYC -1.80%37 Equity-to-Asset is 0.59 as of Dec. 2025, which is 18% below its 10-year median of 0.72. GuruFocus rates ASX:CYC with a GF Score™ of 37/100 and a GF Value™ of A$0.82 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Cyclopharm ranks worse than 57.16% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Cyclopharm's Total Stockholders Equity for the quarter that ended in Dec. 2025 was A$27.11 Mil. Cyclopharm's Total Assets for the quarter that ended in Dec. 2025 was A$46.10 Mil.
Therefore, Cyclopharm's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.59.
The historical rank and industry rank for Cyclopharm's Equity-to-Asset or its related term are showing as below:
ASX:CYC'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.59 Med: 0.72 Max: 0.77
Current: 0.59
During the past 13 years, the highest Equity to Asset Ratio of Cyclopharm was 0.77. The lowest was 0.59. And the median was 0.72.
ASX:CYC's Equity-to-Asset is ranked worse than 57.16% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 0.645
vs ASX:CYC: 0.59
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Cyclopharm Equity-to-Asset Related Terms
Cyclopharm Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Cyclopharm's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CYC vs MCK, COR, CAH: Equity-to-Asset Comparison
For the Medical Devices subindustry, Cyclopharm's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyclopharm Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cyclopharm's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Cyclopharm's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Cyclopharm's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclopharm (ASX:CYC) has a Equity-to-Asset of 0.59 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cyclopharm and its competitors. This is 18% below median its historical median of 0.72. Over the past decade, Cyclopharm's Equity-to-Asset has ranged from 0.59 to 0.77. According to the industry distribution chart, Cyclopharm ranks #487 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 57.2%.
Is Cyclopharm's Equity-to-Asset too high?
Cyclopharm's current Equity-to-Asset of 0.59 is 18% below median its 10-year median of 0.72. Over the past 10 years, this metric has ranged from a low of 0.59 to a high of 0.77. The Medical Devices & Instruments industry median Equity-to-Asset is 0.65. Cyclopharm's value of 0.59 is 8.5% below this industry median. Based on the distribution chart, Cyclopharm ranks #487 out of 852 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Cyclopharm has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyclopharm's Equity-to-Asset compare to MCK and COR?
According to the Medical Devices & Instruments industry distribution chart, Cyclopharm ranks #487 out of 852 companies for Equity-to-Asset. This places Cyclopharm in the lower half of its industry. The industry median Equity-to-Asset is 0.65. Cyclopharm's value of 0.59 is 8.5% below this benchmark. Historically, Cyclopharm's own Equity-to-Asset has ranged from 0.59 to 0.77 over the past decade. While the company's 10-year median is 0.72 vs. the industry median of 0.65, Cyclopharm has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.65, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cyclopharm's current Equity-to-Asset of 0.59 is 8.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cyclopharm and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyclopharm's current Equity-to-Asset is 0.59, which is 18% below median its own 10-year median of 0.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclopharm stock overvalued right now?
Based on GuruFocus' analysis, Cyclopharm (ASX:CYC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.82, compared to a current price of A$0.55 — trading 33.5% below its estimated fair value. The current Equity-to-Asset is 0.59, which is 18% below median its 10-year median of 0.72 and 8.5% below the Medical Devices & Instruments industry median of 0.65. Cyclopharm's overall GF Score™ is 37/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Cyclopharm (ASX:CYC), the current Equity-to-Asset is 0.59 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cyclopharm (ASX:CYC) Overvalued in 2026?
Based on GuruFocus' analysis, Cyclopharm stock appears to be undervalued.
The current stock price of A$0.55 is trading 33.5% below its estimated GF Value™ of A$0.82.
GuruFocus considers Cyclopharm to be Possible Value Trap.
Key valuation signals for ASX:CYC:
Equity-to-Asset: 0.59 (18% below median its 10-year median of 0.72)
GF Value™: A$0.82 vs. price of A$0.55 (33.5% below fair value)
Industry Position: 8.5% below the Medical Devices & Instruments median (#487 of 852)
No single metric tells the full story. See the ASX:CYC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.
37GF Score
Get the complete analysis for ASX:CYC
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CYC has been successfully added to your 
